COMMUNIQUÉS West-GlobeNewswire

FOR SALE: State-of-the-Art cGMP-Qualified Solid Dosage Development and Manufacturing Facility

13/07/2017 - 20:52

The 100,000+ sq.-ft. facility is located on Long Island, less than 50 miles from New York City. COMMACK, NY, July 13, 2017 (GLOBE NEWSWIRE) -- A spacious, technologically advanced facility, conveniently located within [...]

GENFIT - The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d'Information sur la NASH, le 12 juin 2018

13/07/2017 - 19:19

GENFIT - The NASH Education Program TM annonce le lancement de la première Journée Internationale d'Information sur la NASH, le 12 juin 2018 Journée internationale de sensibilisation à la NASH, pathologie silencieuse [...]

GENFIT - The NASH Education ProgramTM announces the launch of the first International NASH Information Day on June 12, 2018: Save the date!

13/07/2017 - 19:19

GENFIT - The NASH Education Program TM announces the launch of the first International NASH Information Day on June 12, 2018: Save the date! A day to raise awareness around NASH, a widespread but little known disease, [...]

The International Association for the Study of Lung Cancer Announces the IASLC 18th World Conference on Lung Cancer

13/07/2017 - 18:22

The only global meeting focused solely on lung cancer will convene thousands in Japan DENVER, July 13, 2017 (GLOBE NEWSWIRE) -- The International Association for the Study of Lung Cancer (IASLC) announced today that the [...]

Oriola Corporation revises guidance for continuing operations adjusted operating profit

13/07/2017 - 18:01

Oriola Corporation Stock Exchange Release 13 July 2017 at 19.00 Oriola Corporation revises guidance for continuing operations adjusted operating profit Despite the recent improvements in the performance of the Consumer [...]

Innate Pharma: Émission de 3 343 748 actions ordinaires au bénéfice de Novo Nordisk A/S en rémunération des droits sur l'anti-C5aR

13/07/2017 - 17:53

ÉMISSION PAR INNATE PHARMA DE 3 343 748 ACTIONS ORDINAIRES AU BÉNÉFICE DE Novo Nordisk A/S EN RÉMUNERATION DES Droits sur L'ANTI-C5 aR L'acquisition de l'anti-C5aR, un anticorps « first-in-class » au stade clinique, [...]

Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR

13/07/2017 - 17:53

Issuance by INNATE PHARMA of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for RIghts in ANTI-C5 aR The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017 [...]

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2017

13/07/2017 - 15:14

Communiqué de presse Villepinte, le 13 juillet 2017 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]

Merus annonce les résultats financiers du premier trimestre 2017 et les résultats d'exploitation de mi-exercice

13/07/2017 - 14:22

Le bilan a été renforcé par un paiement initial de 120 millions de dollars et un achat de 80 millions de dollars d'actions auprès d'Incyte Corporation pour une collaboration de recherche stratégique mondiale en vue de [...]

Crown Bioscience Expands its Life Science Portfolio

13/07/2017 - 14:00

SANTA CLARA, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company [...]

IBA SA : IBA - NOTIFICATION DE TRANSPARENCE

13/07/2017 - 09:25

IBA - NOTIFICATION DE TRANSPARENCE Louvain-la-Neuve, Belgique, 11 juillet 2017, 17h40 - IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce [...]

IBA SA : IBA - TRANSPARENCY NOTIFICATION

13/07/2017 - 09:25

IBA - TRANSPARENCY NOTIFICATION Louvain-la-Neuve, Belgium, July 11, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that [...]

Weifa ASA: Record second-quarter revenues driven by pain and cough & cold

13/07/2017 - 07:30

Oslo, 13 July 2017 Record second-quarter revenues of NOK 98.6 million (NOK 95.3 million) All-organic growth of 3.4% Second-quarter adjusted EBITDA of NOK 22.1 million (NOK 18.6 million) Adjusted EBITDA margin of 22.5% ( [...]

Vistin Pharma ASA : agreement to sell Opioids and CMO business - extended announcement

13/07/2017 - 07:30

Oslo, Norway, 13 July 2017 Reference is made to the stock exchange announcement on 11 July relating to the sale of Vistin Pharma ASA's ("Vistin Pharma" or "Company") opioids and tablet manufacturing business (CMO) ( [...]

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

12/07/2017 - 23:20

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is under FDA priority review; if [...]

Sanofi: Availability of the Pre-quarterly Results Communication

12/07/2017 - 22:30

Availability of the Pre-quarterly Results Communication Paris, France - July 12, 2017 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company's [...]

Sanofi: Pre-quarterly Results Communication

12/07/2017 - 22:30

Paris, July 12, 2017 Pre-quarterly Results Communication Sanofi (EURONEXT: SAN and NYSE: SNY) has compiled the following items for consideration to assist in the financial modeling of the company's Q2 2017 results. [...]

Sanofi : Mise en ligne du document «Pre-quarterly Results Communication »

12/07/2017 - 22:30

Mise en ligne du document «Pre-quarterly Results Communication » Paris, France - Le 12 juillet 2017 - Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « [...]

SPINEWAY : S1 2017 Bilan semestriel du contrat de liquidité

12/07/2017 - 20:51

Communiqué de Presse Ecully, 12 juillet 2017 BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE Au titre du contrat de liquidité confié par la société SPINEWAY à PORTZAMPARC Société de Bourse, à la date du 30 juin 2017 , les [...]